Eliminating 2 Pharmaceutical Stocks

Took a look at ARS Pharmaceuticals (SPRY) recently. This is an interesting company that just launched a nasal-based epinephrine application called neffy late last year. This is an alternative to the needle-based EpiPen for those with acute allergic reactions. Right now, ARS has this market to itself, and epinephrine is a sizable $2-3 billion worldwide market growing at 8+%. However, ARS is presently a one-product company, and there are many similar products in development at other firms. It just doesn't have the kind of competitive protections I want to see from a "Green Dot" pick. I'm also crossing out Kiniksa Pharmaceuticals (KNSA), a clinical-stage biotech with no steady source of revenues just yet.

Watch List

RDDT 10.23%
NTNX 33.26%
CRWD 67.38%
SE 32.25%
SNOW 12.13%
APPF 6.73%
PINS -21.37%

Buy List

SEMR -36.45%
TSM -37.46%
GOOG -49.51%
NYAX -57.29%
MSFT -28.86%
ODD -30.78%
ASR -26.66%
FLYW -35.81%
HRMY -54.32%
YOU -33.54%
ABNB -29.41%
MELI -27.78%
ADBE -38.87%

Hold List

VTEX -17.12%
ZETA -20.17%
CELH 40.60%
TOST 17.90%
CPNG -11.25%
HIMS -8.80%
PAYC -18.77%
MNDY 10.68%
GLBE -20.17%
ZS 28.50%
V -3.09%
ADSK -0.07%
NOW -0.03%
FTNT -2.41%
TEAM -2.35%